Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Education | $113.65 | 10 | 73.5% |
| Food and Beverage | $40.89 | 2 | 26.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $65.35 | 7 | $0 (2022) |
| Genentech USA, Inc. | $24.73 | 1 | $0 (2017) |
| Myovant Sciences Inc. | $23.93 | 1 | $0 (2021) |
| Novocure Inc. | $16.16 | 1 | $0 (2021) |
| Karyopharm Therapeutics Inc. | $12.45 | 1 | $0 (2020) |
| Gilead Sciences, Inc. | $11.92 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $21.00 | 1 | PFIZER INC. ($21.00) |
| 2021 | $52.01 | 3 | Myovant Sciences Inc. ($23.93) |
| 2020 | $12.45 | 1 | Karyopharm Therapeutics Inc. ($12.45) |
| 2019 | $33.95 | 3 | PFIZER INC. ($33.95) |
| 2018 | $10.40 | 3 | PFIZER INC. ($10.40) |
| 2017 | $24.73 | 1 | Genentech USA, Inc. ($24.73) |
All Payment Transactions
12 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/19/2022 | PFIZER INC. | ORGOVYX (Drug) | Education | In-kind items and services | $21.00 | General |
| Category: ONCOLOGY | ||||||
| 06/22/2021 | Novocure Inc. | Optune (Device) | Food and Beverage | Cash or cash equivalent | $16.16 | General |
| Category: Oncology | ||||||
| 06/14/2021 | Myovant Sciences Inc. | ORGOVYX (Drug) | Education | In-kind items and services | $23.93 | General |
| Category: HORMONE THERAPY | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 11/17/2020 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Education | In-kind items and services | $12.45 | General |
| Category: Oncology | ||||||
| 08/02/2019 | PFIZER INC. | XTANDI (Drug) | Education | In-kind items and services | $8.42 | General |
| Category: ONCOLOGY | ||||||
| 04/11/2019 | PFIZER INC. | BESPONSA (Biological) | Education | In-kind items and services | $10.90 | General |
| Category: ONCOLOGY | ||||||
| 02/12/2019 | PFIZER INC. | XTANDI (Drug) | Education | In-kind items and services | $14.63 | General |
| Category: ONCOLOGY | ||||||
| 11/26/2018 | PFIZER INC. | BOSULIF (Drug) | Education | In-kind items and services | $1.14 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 06/26/2018 | PFIZER INC. | BOSULIF (Drug) | Education | In-kind items and services | $8.12 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 06/26/2018 | PFIZER INC. | BOSULIF (Drug) | Education | In-kind items and services | $1.14 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 09/18/2017 | Genentech USA, Inc. | Perjeta (Biological) | Food and Beverage | In-kind items and services | $24.73 | General |
| Category: BioOncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 355 | 635 | $158,216 | $43,240 |
| 2022 | 6 | 328 | 579 | $137,103 | $40,297 |
| 2021 | 4 | 310 | 566 | $120,813 | $40,510 |
| 2020 | 16 | 700 | 2,378 | $497,526 | $96,021 |
All Medicare Procedures & Services
40 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 121 | 327 | $85,461 | $23,405 | 27.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 112 | 156 | $28,719 | $6,965 | 24.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 27 | 47 | $8,225 | $2,981 | 36.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 20 | 26 | $8,993 | $2,625 | 29.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 16 | 16 | $5,487 | $1,574 | 28.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 11 | 11 | $4,959 | $1,523 | 30.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 11 | 15 | $3,900 | $1,431 | 36.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 14 | 14 | $4,620 | $1,289 | 27.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 11 | 11 | $4,508 | $853.38 | 18.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 12 | 12 | $3,344 | $594.18 | 17.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 114 | 299 | $75,619 | $22,146 | 29.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 135 | 186 | $33,046 | $8,807 | 26.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 27 | 27 | $11,733 | $3,858 | 32.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 16 | 20 | $6,620 | $2,220 | 33.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 24 | 35 | $6,125 | $1,978 | 32.3% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 12 | 12 | $3,960 | $1,287 | 32.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 127 | 345 | $75,555 | $25,440 | 33.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 115 | 142 | $21,158 | $6,974 | 33.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 27 | 36 | $10,656 | $4,168 | 39.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 17 | 17 | $7,055 | $2,594 | 36.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 11 | 11 | $3,309 | $671.69 | 20.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 13 | 15 | $3,080 | $661.35 | 21.5% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2020 | 23 | 145 | $177,625 | $24,312 | 13.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 104 | 251 | $73,837 | $19,911 | 27.0% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2020 | 42 | 138 | $73,140 | $15,677 | 21.4% |
About Dr. Douglas Weckstein, MD
Dr. Douglas Weckstein, MD is a Hematology & Oncology healthcare provider based in Concord, New Hampshire. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/07/2005. The National Provider Identifier (NPI) number assigned to this provider is 1710971684.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Douglas Weckstein, MD has received a total of $154.54 in payments from pharmaceutical and medical device companies, with $21.00 received in 2022. These payments were reported across 12 transactions from 6 companies. The most common payment nature is "Education" ($113.65).
As a Medicare-enrolled provider, Weckstein has provided services to 1,693 Medicare beneficiaries, totaling 4,158 services with total Medicare billing of $220,068. Data is available for 4 years (2020–2023), covering 40 distinct procedure/service records.
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology
- Location Concord, NH
- Active Since 09/07/2005
- Last Updated 01/15/2024
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1710971684
Products in Payments
- ORGOVYX (Drug) $44.93
- Perjeta (Biological) $24.73
- XTANDI (Drug) $23.05
- Optune (Device) $16.16
- XPOVIO (Drug) $12.45
- BESPONSA (Biological) $10.90
- BOSULIF (Drug) $10.40
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Concord
Dr. Sudhathi Chichili, M.d, M.D
Hematology & Oncology — Payments: $21,182
Dr. Walailuk Chaiyarat, Md, MD
Hematology & Oncology — Payments: $19,417
Dr. Elizabeth Odumakinde, M.d, M.D
Hematology & Oncology — Payments: $17,590
Dr. Lesley Martin, M.d, M.D
Hematology & Oncology — Payments: $7,915
Jeanna Walsh, Md, MD
Hematology & Oncology — Payments: $3,449
Meghan Steiner, Md, MD
Hematology & Oncology — Payments: $1,234